MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

MeiraGTx (Nasdaq:MGTX) approved an inducement equity grant for new Chief Development Officer Penny Fleck under Nasdaq Listing Rule 5635(c)(4).

The award includes options to purchase 100,000 shares at $9.97 and 100,000 time-based RSUs, with multi-year, employment-based vesting schedules.

News Market Reaction – MGTX

-5.53%

1 alert

-5.53% Session close to close

$882.70M Market Cap

0.0x Rel. Volume

In the May 15 session, MGTX declined 5.53%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.5% in the session following this news. A negative reaction despite this routine i...

Analysis

The stock moved -5.5% in the session following this news. A negative reaction despite this routine inducement grant would fit a pattern where the stock sometimes trades off following corporate updates even when fundamentals are unchanged. Prior events, including the $100 million equity raise and strategic deals, triggered sharp moves like -15.73% on Apr 16, 2026. In such a context, investors might have focused on overhang from recent financings and past volatility rather than on the governance mechanics of this compensation award.

Key Figures

Stock options granted: 100,000 options Option exercise price: $9.97 per share RSUs granted: 100,000 RSUs +1 more

4 metrics

Stock options granted 100,000 options Non-qualified stock options as inducement grant to Chief Development Officer

Option exercise price $9.97 per share Exercise price for 100,000 non-qualified stock options

RSUs granted 100,000 RSUs Time-based restricted stock units granted to new Chief Development Officer

Initial vesting tranche 25% after 1 year Options vest 25% on first anniversary of start date

Historical Context

5 past events · Latest: Apr 16 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Equity offering	Negative	-15.7%	Underwritten offering of 11,111,111 shares at $9.00 for $100M gross.
Apr 16	Asset acquisition	Neutral	-15.7%	Acquisition of bota-vec for XLRP with $25M upfront and milestone terms.
Apr 16	Clinical data update	Positive	-15.7%	Positive three-year Phase 1 AQUAx data for AAV-hAQP1 in xerostomia.
Apr 14	Data presentation	Positive	+17.2%	Announcement of 3-year AQUAx data presentation with detailed efficacy metrics.
Mar 26	BTD & earnings	Positive	-1.2%	FDA Breakthrough Therapy Designation plus 2025 financial and deal updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions: positive clinical and regulatory updates sometimes saw negative price moves, while a data presentation catalyst drew a strong gain.

Recent Company History

Over recent months, MeiraGTx has combined strategic financing with pipeline and regulatory milestones. On Mar 26, 2026, it reported FDA Breakthrough Therapy Designation and 2025 results, yet shares moved -1.18%. A clinical data presentation on Apr 16, 2026 saw a 17.24% gain. That same day, a $100 million equity offering and an acquisition of bota-vec coincided with a -15.73% reaction across several announcements. Against this backdrop, the new CDO inducement grant is a routine corporate governance item rather than a major financial or clinical catalyst.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement grant Under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"comprised of (i) non-qualified stock options to purchase 100,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"(ii) 100,000 time-based restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with an exercise price equal to $9.97, 25% of which will vest and become exercisable on the first anniversary of Ms. Fleck’s start date, with the remaining underlying shares vesting in 36 substantially equal installments each month thereafter, subject to Ms. Fleck’s continued employment with the Company through each applicable vesting date and (ii) 100,000 time-based restricted stock units (“RSUs”), with 50% of the RSUs vesting on the second anniversary of Ms. Fleck’s start date and 25% of the RSUs vesting on each of the third and fourth anniversaries of Ms. Fleck’s start date, subject to Ms. Fleck’s continued employment with the Company through each applicable vesting date.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs uses local delivery of small doses, resulting in disease-modifying effects in both inherited and more common diseases, in the eye, Parkinson’s disease, and radiation-induced xerostomia. MeiraGTx uses its innovative technology in optimization of capsids, promoters, and novel translational control elements to develop best-in-class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 9 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY, and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.

For more information, please visit www.meiragtx.com.

Contacts 

Investors:
MeiraGTx
Investors@meiragtx.com

or

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

What inducement equity grant did MeiraGTx (MGTX) award to Penny Fleck on May 14, 2026?

MeiraGTx granted Penny Fleck stock options for 100,000 shares and 100,000 time-based RSUs. According to MeiraGTx, these equity awards were approved as an inducement to her employment as Chief Development Officer under Nasdaq Listing Rule 5635(c)(4).

What are the vesting terms for Penny Fleck’s MeiraGTx (MGTX) stock options?

Penny Fleck’s 100,000 MeiraGTx stock options vest 25% on the first anniversary of her start date. According to MeiraGTx, the remaining options vest in 36 substantially equal monthly installments, contingent on her continued employment through each vesting date.

What is the exercise price of Penny Fleck’s MeiraGTx (MGTX) stock options?

The exercise price for Penny Fleck’s MeiraGTx non-qualified stock options is $9.97 per share. According to MeiraGTx, these options cover 100,000 ordinary shares and were granted as part of an employment inducement equity package under Nasdaq Listing Rule 5635(c)(4).

How do Penny Fleck’s MeiraGTx (MGTX) RSUs vest over time?

Penny Fleck’s 100,000 MeiraGTx time-based RSUs vest 50% on her second employment anniversary. According to MeiraGTx, 25% then vest on each of the third and fourth anniversaries, subject to her continued employment through the applicable vesting dates.

Why did MeiraGTx (MGTX) use Nasdaq Listing Rule 5635(c)(4) for this equity grant?

MeiraGTx structured Penny Fleck’s equity grant as an inducement award under Nasdaq Listing Rule 5635(c)(4). According to MeiraGTx, these awards were material to her acceptance of the Chief Development Officer role and approved by the board’s Compensation Committee.